Sutro Biopharma logo

Sutro Biopharma (STRO) Q1 2026 Earnings

STRO·Reported May 14, 2026·Before market open

Sutro Biopharma reported Q1 2026 revenue of $14.5M (-16.5% YoY), beat analyst consensus of $8.9M by $5.6M. Diluted EPS came in at $-2.94 (-223.1% YoY), missed the $-2.32 consensus by $0.62.

Revenue
$14.5Mbeat by $5.6M
Consensus: $8.9M
Diluted EPS
$-2.94missed by $0.62
Consensus: $-2.32
SEC

SEC Filings

Earnings release8-K · 0001193125-26-224065
Quarterly report10-Q · 0001193125-26-224170

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Sutro Biopharma's Q1 2026 earnings report.

Sutro Biopharma (STRO) reported Q1 2026 earnings on May 14, 2026 before market open.

Sutro Biopharma reported revenue of $14.5M and diluted EPS of $-2.94 for Q1 2026.

Revenue beat the consensus estimate of $8.9M by $5.6M. EPS missed the consensus estimate of $-2.32 by $0.62.

Compared to the same quarter a year prior, revenue declined 16.5% from $17.4M a year earlier and diluted EPS declined 223.1% from $-0.91.

You can read the 8-K earnings release (0001193125-26-224065) and the 10-Q periodic report (0001193125-26-224170) directly on SEC EDGAR. The filing index links above go to sec.gov.